BIOFRONTERA AG/ADR (NASDAQ:BFRA) Upgraded to Buy by ValuEngine

ValuEngine upgraded shares of BIOFRONTERA AG/ADR (NASDAQ:BFRA) from a hold rating to a buy rating in a research report report published on Tuesday, ValuEngine reports.

Separately, Lake Street Capital cut shares of BIOFRONTERA AG/ADR from a buy rating to a hold rating and decreased their price objective for the stock from $17.00 to $11.00 in a research report on Friday, October 11th.

Shares of BIOFRONTERA AG/ADR stock traded down $2.10 during midday trading on Tuesday, reaching $9.00. The company had a trading volume of 900 shares, compared to its average volume of 50. The stock has a fifty day simple moving average of $11.76 and a 200 day simple moving average of $14.53. The company has a current ratio of 2.48, a quick ratio of 2.23 and a debt-to-equity ratio of 0.90. The company has a market capitalization of $247.75 million, a price-to-earnings ratio of 370.07 and a beta of 0.81. BIOFRONTERA AG/ADR has a 1-year low of $9.00 and a 1-year high of $18.32.

BIOFRONTERA AG/ADR (NASDAQ:BFRA) last released its earnings results on Tuesday, August 27th. The company reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.82. BIOFRONTERA AG/ADR had a net margin of 4.48% and a return on equity of 6.82%. The business had revenue of $7.98 million during the quarter.


Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis.

Recommended Story: If I purchase shares through a brokerage account, am I the holder of record?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BIOFRONTERA AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOFRONTERA AG/ADR and related companies with's FREE daily email newsletter.